Simplifying Global Compliance
FDAnews Drug Daily Bulletin
Pharmaceuticals / Inspections and Audits
Celgene Drops Crohn’s Disease Drug
Oct. 25, 2017
Celgene abandoned development of its Crohn’s disease drug Revolve (mongersen) after disappointing results from a Phase III clinical trial.
The drug failed to pass muster in an interim futility analysis, the company said.
Celgene said it will continue development of other drugs for Crohn’s.
Copyright ©2018. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing